Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Cloudbreak Pharma’s CBT‑004 Phase 2 success raises hopes for first approved vascularized pinguecula therapy Cloudbreak Pharma’s CBT‑004 eye drop hit its Phase 2 targets—find out why it could become the first approved vascularized pinguecula therapy by 2028. byPallavi MadhirajuJuly 21, 2025